55 results about "VZV - Varicella-zoster virus" patented technology

The present invention relates to the identification of the active domain of Herpoxin, a DNA virus-inhibiting-protein which was isolated from cobra venom in U.S. Pat. No. 5,648,339 and has a molecular weight of 13.5 kDa We have isolated a fragment of Herpoxin which contains the active domain and which we have named Herp. Herp mimics the activity of Herpoxin in inhibiting the replication of DNA viruses. A synthetic version of the active fragment was produced having the amino acid sequence Asn-Leu-Tyr-Gln-Phe-Lys-Asn-Met-Ile-Gln. The synthetic version of Herp consisting of ten amino acids inhibits the replication of DNA viruses such as herpes viruses types 1 and 2, cytomegalovirus and varicella zoster virus as well as Tubercle bacilli.

The present invention discloses novel Varicella Zoster Virus (VZV) virus-like particles (VLPs) comprising glycoprotein E of VZV. The invention also discloses vaccine formulations of the VZV-VLPs and methods of inducing an immune response in subjects.

The invention discloses a recombinant varicella zoster virus vaccine, which comprises an amino acid sequence of a recombinant glycoprotein gE extracellular region of a live attenuated VZV strain (OKA strain) gene and a fusion protein formed by a human immunoglobulin Fc segment, and further comprises preparation and an application of the fusion protein, and a corresponding recombinant gene, an eukaryotic expression vector and the like. The fusion protein provided by the invention has good immunogenicity, and can induce generation of a high-level serum neutralizing antibody.

The present invention provides novel antibody sequences that bind Varicella Zoster Virus (VZV) and neutralize VZV infection. The novel sequences can be used for the medical management of VZV infection, in particular for detecting the virus or for preparing pharmaceutical compositions to be used in the prophylactic or therapeutic treatment of VZV infection.

The invention discloses a varicella-zoster virus gE glycoprotein antigen capable of detecting an anti-varicella-zoster virus antibody, particularly an anti-varicella-zoster virus neutralizing antibody, and also discloses application of the antigen in the preparation of a detection reagent for detecting the anti-varicella-zoster virus neutralizing antibody and a corresponding detection reagent kit.

The present invention is directed to a mutated recombinant herpesvirus, e.g., varicella zoster virus (VZV) and simian varicella virus strains or HSV-1 or HSV-2 strains, vaccines containing, and methods for the construction and use thereof to elicit protective immunity in susceptible individuals, wherein the particular herpesvirus is modified to render the virus replication deficient, i.e., the virus substantially or only replicates under defined conditions, by the incorporation of at least one destabilization domain in or fused to a gene essential for herpesvirus replication. The invention particularly relates to the use of the resultant conditionally replication defective herpesviruses, e.g., a mutated VZV strains in vaccine compositions in order to immunize individuals against herpesvirus infection, e.g., in the case of VZV chickenpox and to protect against shingles and zoster, or to prevent the reactivation of VZV or other herpesvirus reactivation and the onset of shingles or another condition relating to the reactivation of another herpesvirus infection, e.g., as a consequence of advanced age, stress, inflammation, drug or other therapy, cancer, or immunodeficiency such as in HIV-AIDS or other diseases resulting in impaired T and / or B cell immunity.

At present, the whole world is a lack of clinically high-efficient and safe broad-spectrum antiviral drugs. A composite of total riboside proteosome component that is prepared from plant chickweed or another stellaria plant and extracted by two resin adsorption methods and a hydroalcohol through a hyperfiltration method, has a molecular weight of 1,000 to 100,000 and is in the form of dark brown powder is used as a safer and more high-efficient broad-spectrum antiviral natural drug. The total protein of the total riboside proteosome component takes up 15% to 25% in the chemical construction, and is made up of 17 amino acids, such as asparaginic acid, glutamic acid, serine, histidine, cystine, methionine, isoleucine and the like in proportions; the proportion of sugar comprises ribose, glucose, galactose and arabinose, and total ribonucleotide takes up 5% to 10% and comprises uracil, thymine, thymidine, guanosine, 2-chloro-adenosine. The composite can be used as a drug for treating virus diseases, such as AIDS virus, hepatitis virus, respiratory syncytial viruses like influenza virus, parainfluenza virus, adenovirus, and the like, including highlypathogenic avian influenza virus, and condyloma virus, enterovirus, mumps virus, herpes simplex virus, herpes zoster virus and varicella-zoster virus. Moreover, the composite has no toxicity, and can be made into more than 10 types of medicine preparations, health products and the like, while causing no environmental pollution in the production process.

The invention provides the use of rosmarinic acid in the preparation of medicines for inhibiting varicella-zoster virus. The rosmarinic acid of the present invention has significant inhibitory effect on VZV, can be used to prepare medicines for inhibiting varicella-zoster virus (VZV), and can also be used to prepare medicines for treating infectious diseases caused by varicella-zoster virus, Such diseases include chickenpox and herpes zoster, postherpetic neuralgia, varicella pneumonia, and acute cerebellar ataxia and encephalitis caused by the varicella-zoster virus, among others.

The invention discloses an LAMP (loop-mediated isothermal amplification) primer combination for detecting four types of eye infected viruses and an application. The primer combination comprises 24 single-stranded DNA molecules shown in sequences from 1 to 24. The invention also discloses the application of the primer combination, and further provides a method for identifying herpes simplex virus type I, herpes simplex virus type II, varicella-zoster viruses or cytomegalo viruses, a method for identifying whether the to-be-detected viruses are the herpes simplex virus type I, the herpes simplex virus type II, the varicella-zoster viruses or the cytomegalo viruses, and a method for identifying whether a to-be-detected sample is infected with the herpes simplex virus type I and / or the herpes simplex virus type II and / or the varicella-zoster viruses and / or the cytomegalo viruses. With the application of LAMP primers and the method, the herpes simplex virus type I, the herpes simplex virus type II, the varicella-zoster viruses and the cytomegalo viruses can be detected rapidly and accurately.

The invention aims at providing a quick detection method of virus titer of varicella zoster virus (VZV). On the basis of traditional VZV antigen double-antibody sandwich ELISA detection method, the quantitative calibration is performed by adding the VZV sample with known titer, and the virus titer of the VZV is determined by drawing a VZV antigen content titer curve. The detection method is simpleand fast in operation, compared with the traditional pfu determination method, the detection efficiency of the VZV titer is greatly improved, and the method is especially suitable for the virus quickdetermination.

The invention discloses application of thymidylate synthase as the target in screening anti-herpes virus drugs. thymidylate synthase can be used for screening drugs resisting Herpes simplex virus-1 (HSV-1), Herpes simplex virus-2 (HSV-2), Varicella zoster virus (VZV), EB virus (Epstein-Barr virus, EBV), Cytomegalovirus (CMV), human herpes virus type VI (HHV-6), human herpes virus type VII (HHV-7) and Kaposi's sarcoma-associated herpesvirus (KSHV) and other herpes viruses. The cell target thymidylate synthase involved in the invention can be used as a new anti-herpes virus target for drug development, and can be applied to treatment or prevention of herpes virus infection.

The invention discloses anti-varicella-zoster virus siRNAs. The anti-varicella-zoster virus siRNAs comprise a positive-sense strand and an antisense strand which are complementary, wherein the nucleotide sequence of the positive-sense strand is one of sequences shown in SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27 and 29, or is a sequence which has the similarity of 90 percent or above with one of the nucleotide sequences of the positive-sense strand; and the nucleotide sequence of the antisense strand of the siRNAs is one of 15 sequences corresponding to the positive-sense strand respectively, or is a complementary sequence of a sequence which has the similarity of 90 percent or above with one of the nucleotide sequences of the positive-sense strand. Moreover, the invention further discloses application of the anti-varicella-zoster virus siRNAs. The siRNAs disclosed by the invention have very high biological activity, can remarkably inhibit replication of varicella-zoster virus, and have the advantages of high functionality and the like.

The invention relates to a preparation method of polysaccharide which is extracted from plants and usage thereof, belonging to the field of biopharmaceuticals. The preparation of polysaccharide comprises extracting total polysaccharide DIP which is extracted and separated from Duchesnea indica and has clear varicella-zoster virus activity resistance property, neutral polysaccharide neutral polysaccharide DIP1 and acidic polysaccharide DIP2 in total polysaccharide, and two major active monomer compositions polysaccharide DIP30 and polysaccharide DIP 60 in acidic polysaccharide DIP2. The raw material of Duchesnea indica has wide source range, easy regeneration, easily-operated preparation method, and high reproducibility. The polysaccharide shows significant inhibition on the varicella-zoster virus, is safe, non-toxic and stable, and is a high-quality anti-viral drug candidate.

The present invention concerns the synthesis and use of formulations of 5-substituted 2, 4-thiazolidinediones, pseudothiohydantoins, and propseudothiohydantoins and 2, 4-thiazolidinediones metforminate salts for topical and systemic treatments of infections caused by herpes simplex viruses and varicella zoster viruses.